 effect gastrin receptor antagonist proglumide survival gastric carcinoma Gastric cancer disease poor prognosis safe effective form therapy advanced disease Evidence abundant gastrin growth gastric colorectal cancer cells vitro vivo blockade gastrin receptors survival xenografted nude mice study gastrin/cholecystokinin receptor antagonist proglumide therapy patients gastric carcinoma Proglumide overall effect survival Mantel-Cox statistic confidence interval proglumide group days days control group significant difference proglumide low affinity gastrin receptor partial agonist activity Drugs specific potent gastrin receptor antagonists available effect survival clinical trials compounds efficacy hormonal control gastrointestinal malignancy